Several new technologies have used synthetic RNAs that leverage the cell’s RNA splicing machinery to drive the expression of gene products. A new study now reports a technique to dynamically and non-invasively monitor gene expression by embedding reporters within introns contained in the parent gene.
References
Zwaka, T. P. & Thomson, J. A. Nat. Biotechnol. 21, 319–321 (2003).
Liu, Z. et al. Sci. Rep. 7, 2193 (2017).
Litterman, A. J. et al. Genome Res. 29, 896–906 (2019).
Nelles, D. A. et al. Cell 165, 488–496 (2016).
Spies, D. & Ciaudo, C. Comput. Struct. Biotechnol. J. 13, 469–477 (2015).
Truong, D.-J. J. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-022-00998-6 (2022).
Martin, M. et al. J. Endocr. Soc. 3, 222–234 (2019).
Schmohl, K. A. et al. Oncotarget 8, 33393–33404 (2017).
Hu, W. L. et al. Nat. Cell Biol. 20, 492–502 (2018).
Clemson, C. M. et al. Mol. Cell 33, 717–726 (2009).
Isobe, M. et al. RNA 26, 251–264 (2020).
Fairbrother, W. G., Yeh, R. F., Sharp, P. A. & Burge, C. B. Science 297, 1007–1013 (2002).
Monteys, A. M. et al. Nature 596, 291–295 (2021).
North, K. et al. Nat. Biotechnol. 40, 1103–1113 (2022).
Dykstra, P. B., Kaplan, M. & Smolke, C. D. Nat. Rev. Genet. 23, 215–228 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.B. declares no competing interests. O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine, Merck and Janssen, and is on the Scientific Advisory Board of Pfizer Boulder, Envisagenics and AIChemy; O.A.-W. has received previous research funding from H3B Biomedicine, Loxo/Lilly and Nurix Therapeutics unrelated to the current manuscript.
Rights and permissions
About this article
Cite this article
Benbarche, S., Abdel-Wahab, O. Harnessing introns to monitor gene expression. Nat Cell Biol 24, 1571–1573 (2022). https://doi.org/10.1038/s41556-022-01003-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-022-01003-w
- Springer Nature Limited